Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PHASE-I STUDY OF SIMULTANEOUS DOSE-ESCALATION AND SCHEDULE ACCELERATION OF CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE USING GRANULOCYTE-COLONY-STIMULATING FACTOR WITH OR WITHOUT ANTIMICROBIAL PROPHYLAXIS IN PATIENTS WITH SMALL-CELL LUNG-CANCER
Autore:
ARDIZZONI A; PENNUCCI MC; DANOVA M; VISCOLI C; MARIANI GL; GIORGI G; VENTURINI M; MEREU C; SCOLARO T; ROSSO R;
Indirizzi:
IST NAZL RIC CANC,DIV MED ONCOL 1,LARGO ROSANNA BENZI XV 10 I-16132 GENOA ITALY UNIV PAVIA I-27100 PAVIA ITALY IRCCS S MATTEO PAVIA ITALY UNIV GENOA,SECT CLIN IMMUNOL INFECT DIS COMPROMISED HOST GENOA ITALY UNIV GENOA,IST ONCOL,SECT RESP ENDOSCOPY GENOA ITALY IST NAZL RIC CANC,DIV RADIOTHERAPY I-16132 GENOA ITALY
Titolo Testata:
British Journal of Cancer
fascicolo: 7, volume: 74, anno: 1996,
pagine: 1141 - 1147
SICI:
0007-0920(1996)74:7<1141:PSOSDA>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
BREAST-CANCER; DOUBLE-BLIND; TRIMETHOPRIM-SULFAMETHOXAZOLE; INFECTION PROPHYLAXIS; ACUTE-LEUKEMIA; CHEMOTHERAPY; INTENSITY; PREVENTION; CARCINOMA; PEFLOXACIN;
Keywords:
SMALL-CELL LUNG CANCER; CHEMOTHERAPY DOSE INTENSITY; GRANULOCYTE COLONY-STIMULATING FACTOR; ANTIMICROBIAL PROPHYLAXIS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
30
Recensione:
Indirizzi per estratti:
Citazione:
A. Ardizzoni et al., "PHASE-I STUDY OF SIMULTANEOUS DOSE-ESCALATION AND SCHEDULE ACCELERATION OF CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE USING GRANULOCYTE-COLONY-STIMULATING FACTOR WITH OR WITHOUT ANTIMICROBIAL PROPHYLAXIS IN PATIENTS WITH SMALL-CELL LUNG-CANCER", British Journal of Cancer, 74(7), 1996, pp. 1141-1147

Abstract

A phase I study was designed to assess whether dose intensity of an 'accelerated' cyclophosphamide-doxorubicin-etoposide (CDE) regimen plusgranulocyte colony-stimulating factor (G-CSF) could be increased further, in an outpatient setting, by escalating the dose of each single drug of the regimen. Patients with previously untreated small-cell lungcancer (SCLC) received escalating doses of cyclophosphamide (C) 1100-1300 mg m(-2) intravenously (i.v.) on day 1, doxorubicin (D) 50-60 mg m(-2) i.v. on day 1, etoposide (E) 110-130 mg m(-2) i.v. on days 1, 2,3 and every 14 days for at least three courses. Along with chemotherapy, G-CSF (filgastrim) 5 mu g kg(-1) from day 5 to day 11 was administered subcutaneously (s.c.) to all patients. Twenty-five patients were enrolled into the study. All patients at the first dose level (C 1100,D 50, E 110 x 3) completed three or more cycles at the dose and schedule planned by the protocol and no 'dose-limiting toxicity' (DLT) was seen. At the second dose level (C 1200, D 55, E 120 x 3) three out of five patients had a DLT consisting of 'granulocytopenic fever' (GCPF). Another six patients were treated at this dose level with the addition of ciprofloxacin 500 mg twice a day and only two patients had a DLT [one episode of documented oral candidiasis and one of 'fever of unknown origin' (FUO) with generalised mucositis]. Accrual of patients proceeded to the third dose level (C 1300, D 60, E 130 x 3) with the prophylactic use of ciprofloxacin. Four out of six patients experienced a DLT consisting of GCPF or documented non-bacterial infection. Accrual of patients at the third dose level was then resumed adding to ciprofloxacin anti-fungal prophylaxis (fluconazole 100 mg daily) and anti-viral prophylaxis (acyclovir 800 mg twice a day) from day 5 to 11. Out of five patients treated three experienced a DLT consisting of severe leucopenia and fever or infection. With a simultaneous dose escalation and schedule acceleration it is indeed possible to take maximum advantage of G-CSF activity and to increase CDE dose intensity by a factor 1.65-1.80 for a maximum of 3-4 courses. The role of antimicrobial prophylaxis in this setting deserves to be investigated further.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/04/20 alle ore 12:05:44